 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...4142434445464748495051...100101» |
- | letrozole / Generic mfg.
Journal: Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer. (Pubmed Central) - Oct 25, 2021
Results showed that there is no interaction between LTZ @ GA-AuNPs and blood. In conclusion, the findings indicate that LTZ @ GA-AuNPs has significant potential as a promising drug delivery carrier for treating breast cancer in postmenopausal women.
- ||| progesterone / Generic mfg., letrozole / Generic mfg.
Does that cover letrozole ? the cancer I had was ostregan and progesterone reactive so have to use this inhibitor. (Twitter) - Oct 22, 2021
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report (Pubmed Central) - Oct 22, 2021
She has since maintained a good quality of life for 2 years and 11 months without serious adverse events. In conclusion, the combination of fulvestrant and palbociclib has a low risk of serious adverse events and is a worthwhile treatment for rapidly progressing, life-threatening multiple bone metastases of breast cancer.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Review, Journal: Oxidative Stress in Polycystic Ovarian Syndrome and the Effect of Antioxidant N-Acetylcysteine on Ovulation and Pregnancy Rate. (Pubmed Central) - Oct 22, 2021
It also results in a mild increase in endometrial thickness in some females. Future studies on a large sample size using NAC alone are highly recommended to evaluate its role as a single-drug therapy for treating infertility in females suffering from PCOS.
- || letrozole / Generic mfg.
Clinical, Journal: Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study. (Pubmed Central) - Oct 22, 2021
Future studies on a large sample size using NAC alone are highly recommended to evaluate its role as a single-drug therapy for treating infertility in females suffering from PCOS. This treatment for endometriosis is a promising new modality that warrants further investigation.
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. (Pubmed Central) - Oct 22, 2021
P3
Compared with KM methods, competing risk analyses result in lower estimates of DFS and DRFS events and similar or modestly lower absolute benefit from experimental endocrine therapy. Over a long time horizon, competing risk methods may be preferable to KM methods when estimating future risk of recurrence in early-stage hormone-sensitive breast cancer.
- || letrozole / Generic mfg., everolimus / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. (Pubmed Central) - Oct 22, 2021
P2
Everolimus plus letrozole might have positive antitumoral immunity effects. Further large randomized controlled trials are needed to confirm our findings.
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Oct 22, 2021
P1/2, N=256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Further large randomized controlled trials are needed to confirm our findings. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Nov 2022
- || Piqray (alpelisib) / Novartis
Trial completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Oct 21, 2021
P2, N=382, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Nov 2022 Trial completion date: Jan 2023 --> Jul 2023
- || tamoxifen / Generic mfg.
Clinical, Journal: Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. (Pubmed Central) - Oct 20, 2021
Treatment with adjuvant T, L, or their sequences was not associated with differences in survival after DR. Significant differences in survival were observed by age, primary tumor size, nodal and PR status, and DFS, and this suggests that traditional baseline high-risk features remain prognostic in the metastatic setting.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case. (Pubmed Central) - Oct 20, 2021
This is an exceedingly rare case of HR+ and HER2- breast cancer with metastasis to the urinary bladder. The late onset of recurrence with bladder metastasis makes this case very unique and to our knowledge only few similar cases have been reported in the literature.
- || Ibrance (palbociclib) / Pfizer
Clinical, Retrospective data, Journal: Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. (Pubmed Central) - Oct 20, 2021
P3
This post hoc analysis of PALOMA-2 demonstrated a favorable effect of palbociclib on PFS and a safety profile consistent with previous observations, regardless of underlying preexisting condition. Pfizer Inc (NCT01740427).
- |||| Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Clinical: Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer:RandomizedTrial | Breast Cancer | @JAMAOnc | @JAMANetworkOpen @OncoAlert https://t.co/CivGjvoaGx (Twitter) - Oct 20, 2021
- ||| Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Parsifal trial confirms similar outcome; letrozole is the preferred partner at present. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Advanced Breast Cancer https://t.co/OUiKGHuu7F via @JAMAOnc part of @JAMANetwork @oncoalert (Twitter) - Oct 20, 2021
- |||| lerociclib (G1T38) / Walvax, Pepper Bio
New P2 trial, Metastases: A Study of Lerociclib in Participants With Advanced Breast Cancer (clinicaltrials.gov) - Oct 19, 2021
P2, N=100, Not yet recruiting, Sponsor: EQRx, Inc.
- | NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Oct 18, 2021
P2, N=19, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Pfizer Inc (NCT01740427). Recruiting --> Active, not recruiting | N=29 --> 19
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Oct 18, 2021
P2, N=144, Recruiting, Sponsor: International Breast Cancer Study Group
Recruiting --> Active, not recruiting | N=29 --> 19 Trial completion date: Mar 2022 --> Aug 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
- || letrozole / Generic mfg.
Clinical, Journal: The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation. (Pubmed Central) - Oct 16, 2021
However, the clinical impact of ovarian stimulation protocol with combined use of gonadotropins and letrozole for fertility preservation remains unclear in this setting. These data underline the importance of establishing the predictive potential of morphological dimorphisms of human oocytes in IVF outcomes.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. (Pubmed Central) - Oct 16, 2021
P3
This analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians.
- || tamoxifen / Generic mfg.
Review, Journal: Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use. (Pubmed Central) - Oct 15, 2021
Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used as adjuvant endocrine therapy in hormone-receptive breast cancer in postmenopausal women...The ocular side effects of tamoxifen use are well documented and were not included...Although these are likely rare side effects, we recommend a high level of clinical suspicion when assessing patients with visual symptoms and on AIs. Larger prospective studies are necessary to further investigate these complications.
- || letrozole / Generic mfg., exemestane / Generic mfg.
Clinical, P2 data, Journal: Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial. (Pubmed Central) - Oct 15, 2021
The type II MRI pattern "fragmentation" was more frequent in the histopathological responder group; and types I and IV in the non-responder group. Type II pattern showed the best endocrine responsiveness and a relatively moderate correlation between sizes obtained from MRI and histology, whereas type IV pattern indicated endocrine resistance but the strongest correlation between MRI and histology.
- ||| Clinical, P3 data, Journal: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. (Pubmed Central) - Oct 15, 2021
P3
Type II pattern showed the best endocrine responsiveness and a relatively moderate correlation between sizes obtained from MRI and histology, whereas type IV pattern indicated endocrine resistance but the strongest correlation between MRI and histology. Safety and efficacy data in this expanded population were consistent with the MONALEESA-2 and MONALEESA-7 trials and support the use of ribociclib plus letrozole in the first-line setting for patients with HR + , HER2- ABC.
- | irosustat (BN 83495) / Ipsen
Journal: Blocking Estrogen Synthesis Leads to Different Hormonal Responses in Canine and Human Triple Negative Inflammatory Breast Cancer. (Pubmed Central) - Oct 14, 2021
In conclusion, letrozole can be an effective treatment for canine and human inflammatory breast cancer. The knowledge of the hormonal profile of breast tumors reflects useful information on the effectiveness of different endocrine treatments.
- Ibrance (palbociclib) / Pfizer, Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P2, N=10, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
The knowledge of the hormonal profile of breast tumors reflects useful information on the effectiveness of different endocrine treatments. Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P1, N=133, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022 Recruiting --> Active, not recruiting
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Metastases: Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P1, N=44, Recruiting, Sponsor: Medical College of Wisconsin
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| letrozole / Generic mfg.
Clinical, Journal, Adverse events: Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer. (Pubmed Central) - Oct 14, 2021
However, the SNP functionality analysis by RegulomeDB provided a 2b rank score for rs7158782, suggesting a potential biological function. Our findings suggest that TCL1A gene polymorphisms may not play any role in the prediction of letrozole-induced AEs in South Indian HR+ breast cancer patients.
- | carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date, Metastases: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P1/2, N=14, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Our findings suggest that TCL1A gene polymorphisms may not play any role in the prediction of letrozole-induced AEs in South Indian HR+ breast cancer patients. Trial primary completion date: Aug 2021 --> Dec 2021
- || letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
#Ribociclib regimen extends OS in advanced #BreastCancer Gabriel N. Hortobagyi, MD, et al. @MDAndersonNews https://t.co/TaLNMp0BqQ @GoHealio #Letrozole (Twitter) - Oct 13, 2021
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
New trial: Efficacy of Letrozole Versus Clomiphene Citrate on Ovulation Induction in Patients With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Oct 13, 2021
P=N/A, N=78, Completed, Sponsor: Nishtar Medical University
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date, Combination therapy, Metastases: Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 12, 2021
P2, N=86, Recruiting, Sponsor: Hunan Cancer Hospital
Trial primary completion date: Aug 2021 --> Dec 2021 Trial primary completion date: Mar 2021 --> Dec 2021
- | Piqray (alpelisib) / Novartis
Trial completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 12, 2021
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Mar 2021 --> Dec 2021 Trial completion date: Sep 2021 --> Feb 2022
- |||| letrozole / Generic mfg., Irene (pyrotinib) / Jiangsu Hengrui Medicine
Clinical, Adverse events, Combination therapy: 📑The effect of combination #therapy with pyrotinib➕letrozole in #HER2-positive/HR-positive mBC #patients has not yet #investigated💡 ➡️This #case shows that this #combination therapy may provide #significant clinical #benefit for these patients with tolerable adverse events👏🤔 (Twitter) - Oct 11, 2021
- || tamoxifen / Generic mfg.
Clinical, Journal: Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer. (Pubmed Central) - Oct 10, 2021
Those with lobular cancer had worse 10-year DR rates compared with those with ductal cancer in the same ROR category. Our results could have an effect on the treatment decisions regarding the addition of chemotherapy for those in the intermediate ROR group.
- Ibrance (palbociclib) / Pfizer, camizestrant (AZD9833) / AstraZeneca, Verzenio (abemaciclib) / Eli Lilly
SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1 m who have not experienced disease progression on first-line therapy (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_362;
Acknowledgments: We thank Julia Mawer, PhD, of Oxford PharmaGenesis, UK, for medical writing assistance, which was funded by AstraZeneca. Funding: The SERENA-6 trial is funded and overseen by AstraZeneca.
- Kisqali (ribociclib) / Novartis
Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_355;
Present accrual and target accrual : Following 8 weeks after initiation of this trial, the first 10 patients have been enrolled. The target accrual is 100 patients with complete study procedures.
- Verzenio (abemaciclib) / Eli Lilly
Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_350;
Both analyses, will be conducted with the Newcombe hybrid score method for confidence intervals. This trial was opened to accrual in May 2021.
- giredestrant (GDC-9545) / Roche
Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_342;
P3
Giredestrant has been demonstrated to be more potent in vitro and achieves higher ER occupancy in vivo than fulvestrant, the only currently approved SERD...Pts are randomized 1:1 to oral 30 mg daily giredestrant or physician’s choice of standard ET (tamoxifen, anastrozole, letrozole, or exemestane, given according to prescribing information)...CONTACT INFORMATION For more information or to refer a patient, email global.rochegenentechtrials@roche.com or call 1-888-662-6728 (USA only). Clinicaltrials.gov number NCT04961996.
- Ibrance (palbociclib) / Pfizer, Apristor (onapristone XR) / Context Therap
Circulating tumor DNA-guided adaptive therapy escalation in ER+ MBC: A phase 1b study with letrozole, palbociclib and onapristone ER (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_334;
We will allot for 5 additional patients to account for inevaluability during the dose escalation and expansion portions of the trial. The trial will be open to enrollment at MSKCC in July 2021.
- amcenestrant (SAR439859) / Sanofi, Ibrance (palbociclib) / Pfizer
AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_332;
P3
Fulvestrant is currently the only SERD available for advanced BC but requires intramuscular administration, limiting the applied dose, exposure and receptor engagement...The study includes men, pre/peri-menopausal (with goserelin) and post-menopausal women...Funding: Sanofi. This abstract was accepted and previously presented at the 2021 American Society of Clinical Oncology Annual Meeting.
- amcenestrant (SAR439859) / Sanofi
I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_296;
Status: This study opened in May 2021. Accrual is ongoing.
- tamoxifen / Generic mfg.
A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2 (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_278;
Background: The introduction of trastuzumab (H) and pertuzumab (P) and ado-trastuzumab emtansine (T-DM1) has drastically improved clinical outcomes in patients (pts) with HER2-positive early breast cancer, allowing to explore chemotherapy-sparing approaches in this population...Hormone receptor-positive pts will be additionally given letrozole (2.5 mg/day orally) if postmenopausal or tamoxifen (20 mg/day orally) plus gonadotropin-releasing hormone analogue if pre-/peri-menopausal or men...The analysis for the primary efficacy and safety endpoints will be conducted with 95% confidence intervals based on Kaplan-Meier estimator. This trial was opened to accrual in May 2021.
- Ibrance (palbociclib) / Pfizer
Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET (Hall 4A) - Oct 9, 2021 - Abstract #SABCS2021SABCS_270;
P3
A standardized clinical PAM50 assay and bioinformatics approach should be used as discrepancies in gene expression platforms and algorithms lead to different results and could misguide treatment decisions. Clinical trial identification: Pfizer (NCT01740427)
- tamoxifen / Generic mfg.
Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_146;
Mutation of TP53 was strongly associated with Ki67 poor response. RNAseq profiling of patients treated with palbociclb as well as letrozole revealed high CCNE1 expression as associated with endocrine resistance.
- Kisqali (ribociclib) / Novartis
Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_136;
P3
Within this high-risk group, early VAF clearance during the first R+L cycle was informative of treatment benefit and associated with a lower risk of progression. Monitoring of ctDNA in patients without baseline mutations demonstrated that the detection of new mutations by FI assessment was associated with worse outcome.
- Kisqali (ribociclib) / Novartis
Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_62;
Consistent with the intent-to-treat population of ML-2, the results of this prespecified exploratory analysis demonstrated an OS benefit with RIB + LET independent of the site and number of metastatic lesions. Table
- paclitaxel / Generic mfg.
Escalating and de-escalation - titrating the right regimen in early stage HER2 positive (Stars at Night Ballroom 1&2) - Oct 9, 2021 - Abstract #SABCS2021SABCS_40;
Regarding de-escalation, TBCRC0023, one of the first chemotherapy-free de-escalation studies in HER2+ EBC, looked at duration of neoadjuvant trastuzumab and lapatinib - in HR+ tumors together with letrozole (+ GNRH if premenopausal)...In TP II, 12x weekly paclitaxel + trastuzumab + pertuzumab achieved a total pCR rate of 57%, whereas the antibodies alone + ET rendered 24%...As demonstrated in ADAPT TP, HER2-enriched subtype is associated with high pCR rates after HER-targeting regimens whereas luminal A and B subtypes have lower pCR rates. In luminal tumors, survival endpoints may thus be more appropriate to fully evaluate de-escalated regimens.In clinical routine, individualized therapy concepts including therapy de-escalation and escalation should always be evidence-based in order not to jeopardize the already excellent survival rates we have achieved over the last decade in HR+ HER2+ EBC.
- || progesterone / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: D-chiro-inositol Induces Ovulation in Non-Polycystic Ovary Syndrome (PCOS), Non-Insulin-Resistant Young Women, Likely by Modulating Aromatase Expression: A Report of 2 Cases. (Pubmed Central) - Oct 8, 2021
Also, the treatment with DCI resulted in a reduction of testosterone levels relative to baseline values. CONCLUSIONS After the 6-week treatment with 1200 mg DCI, ovulation was restored in both women, as confirmed by increased progesterone and LH and endometrial thickening.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. (Pubmed Central) - Oct 8, 2021
The types of first subsequent therapy received by Japanese patients in the palbociclib plus ET and placebo plus ET groups were similar. Further evaluation of subsequent therapy data in the real-world setting is warranted considering the small sample size of this analysis.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: A comparison of oral versus injectable ovarian stimulation in IUI in women ≥38 years of age with decreased ovarian reserve. (Pubmed Central) - Oct 8, 2021
The findings reveal that COH/IUI in older women with decreased ovarian reserve is a viable option (clinical pregnancy rate of 7.5% per cycle), and suggest that oral stimulation agents may be the first-line option, with letrozole having conferred the highest clinical pregnancy rate, 9.1%, which is notable given the typical poor fecundability of this population. However, larger population studies are needed to support this.